Silence Therapeutics (SLN) has released an update.
Silence Therapeutics reported a significant increase in net assets to £94.5 million as of September 2024, despite a rise in operating losses to £22.5 million for the same period. The company’s financial health saw a boost from cash and cash equivalents, which grew to £61.9 million, while R&D expenses weighed heavily on profitability.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.